Dianthus Therapeutics carries the entirety of its pipeline value in a single clinical program against a backdrop of deeply negative free cash flow and business quality well below the minimum acceptable threshold; one recent earnings beat is encouraging but the prior three quarters all missed estimates, and the technical setup lacks the momentum sponsorship that typically precedes a sustained re-rating.
Thesis pillars
- Single Asset Pipeline Concentration↓Deteriorating
- Quality Below Minimum Floor→Stable
- Technical Momentum Failure↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 9, 2026· older than 90 days
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $85.81: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Elevated put/call ratio: 8.38; Below-average business quality.
Dianthus Therapeutics is a clinical-stage biotech developing complement inhibitors for severe autoimmune diseases, with claseprubart (C1s inhibitor) in Phase 3 for CIDP and Phase 2 for gMG and MMN, plus DNTH212 (BDCA2/BAFF-APRIL inhibitor) in Phase 1. The company has no approved... Read more
Sell if holding. Engine safety override at $85.81: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Elevated put/call ratio: 8.38; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.0/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on clean insider activity. Suitability: speculative.
About Dianthus Therapeutics, Inc.
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics' lead clinical candidate, claseprubart, is a selective C1s complement inhibitor running in three active trials: a Phase 3 CIDP program (CAPTIVATE) that achieved its interim responder-rate target in March 2026, a Phase 2 gMG program (MaGic) reporting positive top-line data in September 2025, and a Phase 2 MMN program (MoMeNtum) with top-line results expected in the second half of 2026. Net losses reached $162.3 million in 2025, up from $85.0 million in 2024.
Dianthus earns no product revenue and funds operations entirely through equity issuances. In September 2025, the company completed an underwritten public offering issuing 7,627,879 shares of common stock plus pre-funded warrants to purchase up to 1,112,121 shares; management has also sold 2,626,834 shares under an at-the-market program. Based on its current operating plan, Dianthus believes existing cash, equivalents, and investments will fund operations into 2028. Claseprubart is manufactured through contract development and manufacturing organizations. A second clinical candidate, DNTH212—a bifunctional BDCA2 and BAFF/APRIL inhibitor licensed from Nanjing Leads Biolabs Co., Ltd. on October 16, 2025—entered a Phase 1 study in December 2025 in healthy volunteers and systemic lupus erythematosus patients in China, with top-line healthy volunteer data expected in the second half of 2026. Competitors in gMG include argenx's efgartigimod (Vyvgart/Vyvgart Hytrulo, FDA-approved 2021/2023) and C5 inhibitors eculizumab (Soliris) and ravulizumab (Ultomiris); in CIDP, Vyvgart Hytrulo gained approval in June 2024.
Show full overview
The entirety of Dianthus' near-term value rests on a pivotal Phase 3 readout in CIDP: following the March 2026 CAPTIVATE interim analysis, the company plans to seek regulatory approval to revise the study design and intends to file a Biologics License Application in adult CIDP patients if the trial succeeds. A second binary event is the Phase 3 gMG trial, expected to initiate in mid-2026 with top-line results anticipated in the second half of 2028—a timeline that consumes a significant portion of the company's estimated cash runway through 2028.
See also: Healthcare · Biotechnology
From Dianthus Therapeutics, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated Nov 4, 2026Recent Developments — Dianthus Therapeutics, Inc.
Latest news
- NEWS Dianthus Therapeutics Reports Third Quarter 2026 Financial Results — fiscal.ai Nov 4, 2026
- NEWS Dianthus Therapeutics Sees Phase 3 EMERGE Results For Claseprubart In gMG In 2H 2028 — benzinga Nov 4, 2026 neutral
- NEWS Dianthus Therapeutics Says Phase 3 CAPTIVATE Trial In CIDP Now Needs Fewer Than 200 Patients In Part A; Part A Results B — benzinga Nov 4, 2026 neutral
- NEWS Dianthus Therapeutics Sees Phase 2 MoMeNtum Results For Claseprubart In MMN In December; Plans Phase 3 In 2027 — benzinga Nov 4, 2026 neutral
- NEWS Dianthus Therapeutics Ends Q3 With About $1.2B In Cash & Investments; Sees Runway Into 2030 — benzinga Nov 4, 2026 positive
Latest item Nov 4, 2026 · Generated 2026-11-05T11:39:29Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineclaseprubart10-K Item 1A: 'We are substantially dependent on the success of our most advanced product candidate, claseprubart'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $85.81: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Elevated put/call ratio: 8.38; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $79.80. Score 6.0/10, moderate confidence.
Analyst target: $125.16 (+45.9% upside). Prior stop was $79.80. Stop-loss: $79.80.
Concentration risk — Pipeline: claseprubart; Quality below floor (3.5 < 4.0).
Dianthus Therapeutics, Inc. trades at a P/E of N/A (forward -18.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
24 analysts rate DNTH, with a consensus score of 4.4/5. 16 analysts publish price targets averaging $139.
What does Dianthus Therapeutics, Inc. do?Dianthus Therapeutics is a clinical-stage biotech developing complement inhibitors for severe autoimmune diseases, with...
Dianthus Therapeutics is a clinical-stage biotech developing complement inhibitors for severe autoimmune diseases, with claseprubart (C1s inhibitor) in Phase 3 for CIDP and Phase 2 for gMG and MMN, plus DNTH212 (BDCA2/BAFF-APRIL inhibitor) in Phase 1. The company has no approved products and reported net losses of $162.3 million in 2025 and $85.0 million in 2024.